ArticleDiabetology & metabolic syndrome2025
Oncostatin M mediates the causal relationship between obesity and chronic kidney disease: evidence from Mendelian randomization and experimental validation.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundObesity is a risk factor for chronic kidney disease (CKD). One of the main features of obesity-related glomerulopathy (ORG) is the chronic low-grade inflammatory state. Herein, we aimed to explore the inflammatory proteins that potentially serve as mediators between obesity and CKD by Mendelian randomization (MR) analysis, and to validate the findings by clinical research and animal experiments.
methodsTwo-step MR and mediation analyses were performed to assess the causal relationships between obesity-related traits and circulating inflammatory proteins and CKD. After identifying Oncostatin M (OSM) as the potential mediator, serum OSM levels of human participants with normal weight, overweight or obesity were assessed. Expression of OSM receptor (OSMR) in the human kidney was validated using publicly available scRNA-seq data. The protein expression and activation of OSMR in the kidneys of obese mice fed a high-fat diet (HFD) were validated by Western blotting.
resultsCirculating OSM level is a potential mediator between body mass index (BMI) and CKD, with a mediated proportion of 4.48%. In the clinical study, serum OSM levels were elevated in obese individuals and associated with both BMI and proteinuria. The scRNA-seq analysis found elevated OSMR expression in obese kidneys, with the highest expression level in endothelial cells. The in vivo experiment showed increased protein expression of OSMR, JAK1, and phospho-JAK1 in the kidney of obese mice, indicating activation of OSM/OSMR signaling.
conclusionsWe identified circulating OSM levels as a potential mediator in the causal link between obesity and CKD. OSM/OSMR may be a promising target for developing therapeutic strategies for ORG.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.